Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CDX-014 |
Synonyms | |
Therapy Description |
CDX-014 is a monoclonal antibody against the extracellular domain of T-cell immunoglobulin mucin-1 (TIM-1) in conjugation with the cytotoxin monomethyl auristatin E (MMAE), which may results in cytotoxicity specific to TIM-1 over-expressing tumor cells (PMID: 27671527, PMID: 32472319). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CDX-014 | CDX-014 is a monoclonal antibody against the extracellular domain of T-cell immunoglobulin mucin-1 (TIM-1) in conjugation with the cytotoxin monomethyl auristatin E (MMAE), which may results in cytotoxicity specific to TIM-1 over-expressing tumor cells (PMID: 27671527, PMID: 32472319). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02837991 | Phase Ib/II | CDX-014 | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Advanced or Metastatic Renal Cell Carcinoma | Terminated | USA | 0 |